

Curvus Announces 510(K) Clearance of its Completely Wireless Arrhythmia Monitoring Device

Boston, Massachusetts, December 13, 2010 – Curvus, Inc., the wholly-owned subsidiary of WPR Medical AS and leading developer of real-time, wireless solutions for remotely monitoring clinical information of patients across a range of biomedical parameters, announced today that it has received 510(K) clearance by U.S. Food and Drug Administration for its Curvus Arrhythmia Monitoring Device (“C-AD”). The C-AD is a highly differentiated wireless cardiac arrhythmia monitor, which, with its patent-secured design, is able to capture continuous, real-time ECG readings over the broadest spectrum of patient activity with minimal noise artifacts.

Borge Bogaard, Chief Executive Officer of Curvus, said, "We are thrilled that Curvus has achieved regulatory clearance and can now be commercialized in the US. Due to the rapidly increasing burden of atrial fibrillation worldwide, we believe that expanded monitoring and diagnosis of these cardiac events combined with the release of several new anticoagulant drugs, will make a major contribution to control the disastrous worldwide burden of stroke. With its 100% wireless design and ability to transmit clear, actionable data whether the patient is resting, running a marathon or showering, we believe Curvus is well-positioned to expand monitoring broadly."

The C-AD is a fully-integrated, wireless cardiac monitoring system. Using patented shielding and antenna technology, the device can reliably transmit data from a single-lead sensor with two electrodes affixed to the patient's body to a mobile recorder using the 2.4 GHz frequency. This truly wireless solution facilitates unencumbered cardiac monitoring of patients during the activities of daily living. Because of its inconspicuous nature, the Curvus wireless solution also eliminates the stigma associated with wearing a Holter monitor. The Curvus software suite enhances and expedites analysis of the ECG data with a data analysis package that incorporates clinically established arrhythmia parameters.

As part of its strategic roadmap and plans to launch commercially in the US, Curvus has retained the investment bank, Benning Associates, LLC in Boston, Massachusetts (<http://www.benningllc.com>) to assist the Company in securing growth financing and facilitating discussions with strategic partners.

About Curvus, Inc.

Founded in 2003, Curvus is a leader in the design, development and commercialization of real-time, wireless solutions for remotely monitoring clinical information of patients across a range of biomedical parameters. The Company's current focus, and the first application of the Curvus platform, is the Curvus Arrhythmia Monitoring Device, which has CE Mark approval in Europe and received 510(K) clearance in the US. The technology is based on a dedicated Body Area Network (“BAN”), where many sensors can be connected to the same base data receiver. The unique BAN technology facilitates coordination with future sensors and the ability to monitor additional physiological parameters. Curvus has operations in Boston, Massachusetts and Arendal, Norway, the headquarters of its parent company, WPR Medical AS.

For further information please contact:

Borge Bogaard at borge.bogaard@curvus.com or + 1 603 531 3190